Finance

Beta
Lists
GNLX:NASDAQ
Genelux Corp
$3.05
-0.65%
(-0.020) 1D
$3.05
+0.07% (+0.0022)
After hours
Closed: May 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GNLX...
Open
$3.08
High
$3.09
Low
$3.02
Mkt. cap
136.76M
Avg. vol.
156.14K
Volume
115.16K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.85
Beta
0.51
Shares outstanding
44.84M
No. of employees
26
Open
$3.08
High
$3.09
Low
$3.02
Mkt. cap
136.76M
Avg. vol.
156.14K
Volume
115.16K
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.85
Beta
0.51
Shares outstanding
44.84M
No. of employees
26
News stories
From sources across the web
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
8.00K
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.76M
4.74M
5.55M
5.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.03M
3.45M
3.87M
3.39M
Operating expense
7.79M
8.19M
9.42M
9.17M
Total operating expenses
7.79M
8.19M
9.42M
9.17M
Operating income
-7.79M
-8.19M
-9.41M
-9.17M
Other non operating income
112.00K
69.00K
37.00K
70.00K
EBT including unusual items
-7.46M
-7.95M
-9.25M
-8.93M
EBT excluding unusual items
-7.46M
-7.95M
-9.25M
-8.93M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.46M
-7.95M
-9.25M
-8.93M
Net profit margin
-
-
-115,587.50%
-
Earnings per share
-0.20
-0.21
-0.24
-0.20
Interest and investment income
224.00K
175.00K
128.00K
173.00K
Interest expense
-
-
-
-
Net interest expenses
224.00K
175.00K
128.00K
173.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.73M
-8.13M
-9.35M
-9.16M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer